Research ArticleTheranostics
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P. Nicolas, Lisa McDougall, Felix Kaul, Michal Cachovan, A. Hans Vija, Roger Schibli, Susanne Geistlich, Anne Schumann, Tilman Rau, Katharina Glatz, Martin Behe, Emanuel R. Christ and Damian Wild
Journal of Nuclear Medicine April 2020, 61 (4) 520-526; DOI: https://doi.org/10.2967/jnumed.119.233031
Christof Rottenburger
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Guillaume P. Nicolas
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
Lisa McDougall
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Felix Kaul
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
Michal Cachovan
3Siemens Healthcare GmbH, Forchheim, Germany
A. Hans Vija
4Molecular Imaging, Siemens Medical Solutions USA, Inc., Hoffman Estates, Illinois
Roger Schibli
5Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH, Zurich, Switzerland
Susanne Geistlich
6Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland
Anne Schumann
73B Pharmaceuticals GmbH, Berlin, Germany
Tilman Rau
8Institute of Pathology, University of Bern, Bern, Switzerland
Katharina Glatz
9Institute of Pathology, University Hospital Basel, Basel, Switzerland; and
Martin Behe
6Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland
Emanuel R. Christ
2Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
10Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland
Damian Wild
1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
2Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 4
April 1, 2020
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P. Nicolas, Lisa McDougall, Felix Kaul, Michal Cachovan, A. Hans Vija, Roger Schibli, Susanne Geistlich, Anne Schumann, Tilman Rau, Katharina Glatz, Martin Behe, Emanuel R. Christ, Damian Wild
Journal of Nuclear Medicine Apr 2020, 61 (4) 520-526; DOI: 10.2967/jnumed.119.233031
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger, Guillaume P. Nicolas, Lisa McDougall, Felix Kaul, Michal Cachovan, A. Hans Vija, Roger Schibli, Susanne Geistlich, Anne Schumann, Tilman Rau, Katharina Glatz, Martin Behe, Emanuel R. Christ, Damian Wild
Journal of Nuclear Medicine Apr 2020, 61 (4) 520-526; DOI: 10.2967/jnumed.119.233031
Jump to section
Related Articles
Cited By...
- Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer
- Signaling Network Response to {alpha}-Particle-Targeted Therapy with the 225Ac-Labeled Minigastrin Analog 225Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors